Minerva Neurosciences announced the appointment of Dr. Inderjit Kaul to its board of directors and as a consultant for future clinical development.
The company recently raised $200 million in a private placement for a Phase 3 trial of roluperidone for schizophrenia.
Dr. Kaul's expertise in drug development, especially in schizophrenia, aligns with Minerva's focus on central nervous system disorders.
Appointment of Dr. Inderjit Kaul
Dr. Kaul appointed to Minerva Neurosciences' board and as a consultant for clinical development.
Successful Fundraising
Successfully raised $200 million to support a Phase 3 trial for roluperidone.
Focus on Schizophrenia Treatment
Concentrating on developing therapies for negative symptoms in patients with schizophrenia.
- Dr. Kaul's experience strengthens Minerva's clinical operations and development of roluperidone.
- Appointment of additional board members with schizophrenia clinical trial expertise to support Phase 3 trial.
The appointment of Dr. Kaul and the successful fundraising highlight Minerva Neurosciences' commitment to advancing treatments for schizophrenia. With a focus on addressing negative symptoms, the company is poised for significant developments in the field.